Analystreport

Turning Point Therapeutics (NASDAQ: TPTX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $90.00 to $120.00. They now have an "outperform" rating on the stock.

Turning Point Therapeutics, Inc. - Common stock  (TPTX) 
Last turning point therapeutics, inc. - common stock earnings: 3/16 09:00 am Check Earnings Report